However, advancements in the field of genetics have unraveled responsive prostate cancer sites besides the AR (Ren, Chen, et al. 2023; Ren, Li, et al. 2023), such as poly (ADP‐ribose) polymerase, which is a target for PAPP inhibitor drugs for DNA repair abnormalities, and PD1, whose blockage can be employed in incompatible repair insufficiency (de Bono et al. 2020). This evidence concerns the gene AR and prostate cancer.